Category: Approval/Launch Region: North America · United States Company: Astrazeneca Lp

US FDA approves AstraZeneca And Daiichi Sankyos Enhertu as first HER2-directed therapy for patients with previously treated HER2-mutant metastatic NSCLC

By, Admin 1 min read
Share
US FDA approves AstraZeneca And Daiichi Sankyos Enhertu as first HER2-directed therapy for patients with previously treated HER2-mutant metastatic NSCLC
AstraZeneca and Daiichi Sankyo

Found this useful? Share it with your team.

Welcome Back Sign in to Continue

Don't Have an Account? Sign Up!
Forgot Password?

Create your Account!

Don't Have an Account? Sign Up!